What's new in enuresis?
Acta Paediatr Taiwan
; 43(1): 6-9, 2002.
Article
en En
| MEDLINE
| ID: mdl-11890230
ABSTRACT
UNLABELLED Treatment of primary nocturnal enuresis (PNE) using desmopressin (dDAVP) is based upon the hypothesis that antidiuretic hormone (arginine vasopressin (AVP) secretion is insufficient during the night. Persisting doubts about the theoretical background of this treatment gave reason to different studies In a first study, AVP regulation in children with PNE was investigated. AVP levels after fluid restriction were compared to those of healthy controls. In order to maintain osmolality, the plasma AVP concentrations of the enuretic children rose to significant higher levels than in the controls. In a second study, the short-time memory of children treated with dDAVP because of PNE was measured. Children under dDAVP showed a significantly better short- time memory. CONCLUSION:
The results are consistent with the established fact that AVP secretion is a function of plasma osmolality. They contradict the hypothesis that enuretic children have a AVP deficiency which has to be supplemented. Rather, the results point to central action of dDAVP, a defect at the central AVP receptor level or the signal transduction pathway.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Fármacos Renales
/
Desamino Arginina Vasopresina
/
Enuresis
Tipo de estudio:
Etiology_studies
Límite:
Child
/
Humans
Idioma:
En
Revista:
Acta Paediatr Taiwan
Asunto de la revista:
PEDIATRIA
Año:
2002
Tipo del documento:
Article
País de afiliación:
Alemania